US Congress House Bill 2368 (Prior Session Legislation)

---

Spectrum: Moderate Partisan Bill (Republican 5-1)
Status: Introduced on May 4 2017 - 25% progression, died in committee
Action: 2017-06-07 - Referred to the Subcommittee on Crime, Terrorism, Homeland Security, and Investigations.
Pending: House Subcommittee on Crime, Terrorism, Homeland Security, And Investigations Committee
Text: Latest bill text (Introduced) [PDF]

Right to Try Act This bill requires the federal government to allow unrestricted manufacturing, distribution, prescribing, and dispensing of experimental drugs, biological products, and medical devices that are authorized by state law and intended to treat terminally ill patients. Patients receiving these treatments must be certified by a physician as having exhausted all other treatment options and as being at greater risk from their medical condition than the treatment. The physician must explain the treatment to the patient, including that the treatment is experimental, and the patient, or the patient's legal representative, must acknowledge the explanation. A manufacturer, distributor, prescriber, dispenser, possessor, or user of such a treatment has no liability regarding the treatment. The outcome of manufacture, distribution, prescribing, dispensing, possession, or use of such a treatment may not be used by a federal agency to adversely impact review or approval of the treatment. The treatment must: (1) have successfully completed a phase 1 (initial, small scale) clinical trial; (2) remain under investigation in a clinical trial approved by the Food and Drug Administration (FDA); and (3) not be approved, licensed, or cleared for sale by the FDA.

Right to Try Act

Rep. Brian Fitzpatrick [R-PA]	Sen. Kyrsten Sinema [I-AZ]	Rep. Andy Biggs [R-AZ]	Rep. Mark Sanford [R-SC]
Rep. Lloyd Smucker [R-PA]	Rep. Alexander Mooney [R-WV]

Date	Chamber	Action
2017-06-07	House	Referred to the Subcommittee on Crime, Terrorism, Homeland Security, and Investigations.
2017-06-07	House	Referred to the Subcommittee on the Constitution and Civil Justice.
2017-05-05	House	Referred to the Subcommittee on Health.
2017-05-04	House	Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2017-05-04	House	Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2017-05-04	House	Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2017-05-04	House	Introduced in House

HB878 (Related) 2017-03-02 - Referred to the Subcommittee on Crime, Terrorism, Homeland Security, and Investigations.
SB204 (Related) 2018-05-30 - Became Public Law No: 115-176.
HR905 (Similar To) 2018-05-22 - Motion to reconsider laid on the table Agreed to without objection.

Type	Source
Summary	https://www.congress.gov/bill/115th-congress/house-bill/2368/all-info
Text	https://www.congress.gov/115/bills/hr2368/BILLS-115hr2368ih.pdf